Krystal Biotech

Krystal Biotech

Krish Krishnan, a biochemist with a history of guiding drugs through the FDA at previous ventures, launched Krystal Biotech in Pittsburgh in 2015. The company is built around a herpes-simplex virus type 1 (HSV-1) vector platform. Unlike the adeno-associated viruses (AAVs) most gene therapy companies use — which typically generate neutralizing antibodies after one dose — the HSV-1 backbone is engineered to be re-dosable. That makes the platform a genuine structural outlier in the gene therapy landscape. The wealth origin is institutional venture capital and public-market funding, not a family fortune. The company's strategy is unusual for biotech: it started with a condition too small for most large pharma companies to prioritize. Its lead product, Vyjuvek (beremagene geperpavec), is a topical gel that delivers a functional copy of the COL7A1 gene to skin cells, treating dystrophic epidermolysis bullosa (DEB) — a rare, blistering pediatric disease. The FDA approved Vyjuvek in May 2023. By the end of that year, the company generated roughly $50 million in product revenue, making it one of the few rare-disease launches to achieve meaningful commercial traction in its first two quarters. Beyond DEB, Krystal has expanded its pipeline to aesthetic medicine and larger dermatology indications, filing an IND for a second topical gene therapy targeting aesthetic wrinkles in early 2024. The geographic footprint is heavily US-focused, with all manufacturing in a dedicated Pittsburgh facility and no disclosed clinical operations outside North America. Krystal is listed on Nasdaq and employs approximately 200 people. The company has not disclosed a structured family-office or multi-family-office vehicle, but its commercial revenue and a strong cash position — roughly $700 million in cash and equivalents exiting 2023 — give it a balance sheet that functions like a self-funding investment engine. In June 2024: Filed an Investigational New Drug application for KB301, an aesthetic gene therapy that targets type III collagen to improve skin appearance (per the firm, June 2024). The Pittsburgh headquarters serves as both corporate hub and manufacturing center — an integrated structure that gives Krystal more control over production costs than many biotechs that outsource to CDMOs. The firm's structural differentiator is its balance-sheet independence. Most mid-cap biotechs burn venture capital until a liquidity event or partnership. Krystal turned a rare-disease approval into positive cash flow within months, then fed that capital directly into pipeline expansion and manufacturing scale. That makes its capital-allocation decisions look more like an industrial operator's than a traditional biotech's — a posture reinforced by the husband-and-wife leadership team of Krish and Suma Krishnan, who combine scientific oversight with operational control.